Serum levels of interleukin-22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study

Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular diabetology 2017-01, Vol.16 (1), p.17, Article 17
Main Authors: Herder, Christian, Kannenberg, Julia M, Carstensen-Kirberg, Maren, Huth, Cornelia, Meisinger, Christa, Koenig, Wolfgang, Peters, Annette, Rathmann, Wolfgang, Roden, Michael, Thorand, Barbara
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
Cardiovascular Diseases - blood
Cardiovascular Diseases - diagnosis
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - prevention & control
Cross-Sectional Studies
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - epidemiology
Diabetes Mellitus, Type 2 - prevention & control
Female
Germany - epidemiology
Humans
Incidence
Interleukin-22
Interleukins - blood
Linear Models
Male
Metabolic Syndrome - blood
Metabolic Syndrome - diagnosis
Metabolic Syndrome - epidemiology
Metabolic Syndrome - prevention & control
Middle Aged
Multivariate Analysis
Odds Ratio
Original Investigation
Prognosis
Prospective Studies
Protective Factors
Risk Assessment
Risk Factors
Time Factors
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interleukin-22 (IL-22) has beneficial effects on body weight, insulin resistance and inflammation in different mouse models, but its relevance for the development of type 2 diabetes in humans is unknown. We aimed to identify correlates of serum IL-22 levels and to test the hypothesis that higher IL-22 levels are associated with lower diabetes incidence. Cross-sectional associations between serum IL-22, cardiometabolic risk factors and glucose tolerance status were investigated in 1107 persons of the population-based KORA F4 study. The prospective association between serum IL-22 and incident type 2 diabetes was assessed in 504 initially non-diabetic study participants in both the KORA F4 study and its 7-year follow-up examination KORA FF4, 76 of whom developed diabetes. Male sex, current smoking, lower HDL cholesterol, lower estimated glomerular filtration rate and higher serum interleukin-1 receptor antagonist were associated with higher IL-22 levels after adjustment for confounders (all P 
ISSN:1475-2840
1475-2840
DOI:10.1186/s12933-017-0498-6